Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic ar... Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.483 | -9.15639810427 | 5.275 | 5.365 | 4.752 | 192939 | 4.99725601 | DE |
| 4 | -0.383 | -7.40096618357 | 5.175 | 5.365 | 4.448 | 284968 | 4.90695214 | DE |
| 12 | 0.501 | 11.6756000932 | 4.291 | 5.78 | 4.016 | 303578 | 4.95320754 | DE |
| 26 | -0.508 | -9.58490566038 | 5.3 | 6.708 | 4.001 | 334449 | 5.26393453 | DE |
| 52 | -2.248 | -31.9318181818 | 7.04 | 7.848 | 4.001 | 331424 | 5.82981959 | DE |
| 156 | -18.208 | -79.1652173913 | 23 | 24.44 | 4.001 | 351842 | 9.13077344 | DE |
| 260 | -29.948 | -86.2061024755 | 34.74 | 45.83 | 4.001 | 384160 | 17.26881595 | DE |
tweedking
6分前
goodietime
6分前
Denn55
7分前
BRICK_TOP
8分前
ombowstring
9分前
goodietime
10分前
jimr1717
12分前
gmac8625
12分前
satter
12分前
Slightlybetter0
13分前
STOCKENTHUSIASM123
14分前
STOCKENTHUSIASM123
15分前
dewophile
16分前
brooktrail1933
20分前
Flip it
20分前
TightCoil
23分前
DocKB
24分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。